Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-181 China Extension
NCT03933449Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2016
- Primary completion
- Feb 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in esophageal carcinoma, esophagogastric junction carcinoma, sponsored by Merck & Co.. Started Dec 2016; status: completed.
02
Drugs
03
Conditions
esophageal carcinomaesophagogastric junction carcinoma
Beyond the preview
Go deeper on NCT03933449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03933449.